Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)

startup_marketing

Last week, Durata Therapeutics, Inc. (Nasdaq:DRTX) announced that DALVANCE (dalbavancin) for injection is now available for use to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI). DALVANCE was approved by the U.S. Food and Drug Administration (FDA) on May 23, 2014 and was the first drug approved as a Qualified Infectious Disease Product (QIDP). Durata began shipping DALVANCE to its distributors earlier this week.

Continue reading

Express Scripts Claims New Hepatitis C Therapy will Cost Illinois $2.3B

wpid-Photo-20140711095706.jpg

According to a report that Express Scripts released state legislatures will need to find billions in their budgets to purchase costly new hepatitis C therapy, according to a new state-by-state analysis released today by Express Scripts (NASDAQ: ESRX). But their report is near sighted only looking at the immediate costs of the prescription, instead of the longterm cost stagings this therapy can provide.

Continue reading

Framing Up Capital Efficiency In Early Stage Biotech

Originally posted on Forbes

95012103-e1403297793936-1024x767

Capital efficiency has become a mantra at Atlas, one shared by a number of other early stage biotech investors. It’s a term often repeated in discussions about building young companies, and yet it has become clear that there’s no consistent definition of what the term means.

Continue reading